OR SB764 | 2021 | Regular Session

Status

Completed Legislative Action
Spectrum: Moderate Partisan Bill (Democrat 15-2)
Status: Failed on June 26 2021 - 100% progression
Action: 2021-06-26 - In committee upon adjournment.
Text: Latest bill text (Engrossed) [PDF]

Summary

Provides that court must presume that resolution agreement that ends dispute over alleged infringement of patent or violation of other protection for protected drug has anticompetitive effects if alleged infringer receives item of value as part of or in connection with resolution agreement or if alleged infringer agrees to limit or stop researching, developing, manufacturing, marketing or selling competing drug. Provides that Attorney General and] court must presume that resolution agreement that ends dispute over alleged infringement of patent or violation of other protection for protected drug has anticompetitive effects if alleged infringer receives item of value as part of or in connection with resolution agreement or if alleged infringer agrees to limit or stop researching, developing, manufacturing, marketing or selling competing drug. Specifies basis on which party to resolution agreement may overcome presumption. Provides that Attorney General may bring action to recover civil penalty for violations of Act in amount that is equivalent to three times value of item of value that alleged infringer received or $10 million per violation, whichever is greater. Takes effect on 91st day following adjournment sine die.].

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Relating to agreements that lead to anticompetitive behavior in the market for pharmaceutical drugs.

Sponsors


Roll Calls

2021-05-27 - House - House Committee Without recommendation as to passage and be referred to Rules (Y: 10 N: 0 NV: 0 Abs: 0) [PASS]
2021-04-22 - Senate - Senate Third Reading (Y: 16 N: 12 NV: 0 Abs: 2) [PASS]
2021-04-22 - Senate - Senate Motion to Refer (Y: 11 N: 17 NV: 0 Abs: 2) [FAIL]
2021-04-07 - Senate - Senate Committee Do pass with amendments. (Printed A-Eng.) (Y: 3 N: 2 NV: 0 Abs: 0) [PASS]

History

DateChamberAction
2021-06-26HouseIn committee upon adjournment.
2021-06-02HouseReferred to Rules by order of Speaker.
2021-06-02HouseWithout recommendation as to passage and be referred to Rules.
2021-05-27HouseWork Session held.
2021-05-20HousePublic Hearing held.
2021-05-18HousePublic Hearing held.
2021-05-04HouseReferred to Health Care.
2021-04-27HouseFirst reading. Referred to Speaker's desk.
2021-04-22SenateThird reading. Carried by Patterson. Passed. Ayes, 16; Nays, 12--Anderson, Boquist, Findley, Girod, Hansell, Johnson, Kennemer, Knopp, Linthicum, Robinson, Thatcher, Thomsen; Excused, 2--Frederick, Heard.
2021-04-22SenateMotion to refer to Committee on Ways and Means failed. Ayes, 11; Nays, 17--Beyer, Burdick, Dembrow, Gelser, Golden, Gorsek, Jama, Johnson, Lieber, Manning Jr, Patterson, President Courtney, Prozanski, Riley, Steiner Hayward, Taylor, Wagner; Excused, 2--Frederick, Heard.
2021-04-21SenateSecond reading.
2021-04-19SenateRecommendation: Do pass with amendments. (Printed A-Eng.)
2021-04-07SenateWork Session held.
2021-03-03SenatePublic Hearing held.
2021-02-22SenateReferred to Health Care.
2021-02-18SenateIntroduction and first reading. Referred to President's desk.

Oregon State Sources


Bill Comments

feedback